Valuation: Genome & Company

Market Cap 221B 164M 147M 136M 124M 233M 15.55B 237M 1.64B 640M 8.11B 616M 603M 25.96B P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 203B 151M 135M 125M 114M 214M 14.29B 218M 1.5B 588M 7.46B 566M 554M 23.86B EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
85.27%
Yield 2024 *
-
Yield 2025 -
09-20 Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index CI
04-13 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
04-02 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
03-12 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
25-09-21 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
25-08-20 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
25-07-10 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
25-04-27 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
25-04-23 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
24-07-18 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-07-16 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
1 day-11.16%
1 week-22.85%
Current month-17.25%
1 month+23.94%
3 months+8.76%
6 months-40.90%
Current year-38.66%
1 week 4,170
Extreme 4170
5,480
1 month 2,925
Extreme 2925
5,930
Current year 2,925
Extreme 2925
10,180
1 year 2,585
Extreme 2585
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
20,300
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 2015-09-23
Chief Executive Officer 55 2015-09-23
Director TitleAgeSince
Director/Board Member 55 2015-09-23
Director/Board Member 62 -
Director/Board Member 63 2025-03-27
Date Insider Type Main position Quantity % Market Cap. Importance
5/9/25 Don

Chief Executive Officer

100,000 0.3217%
5/9/25 Free

Director

40,000 0.1287%
5/9/25 Free

Public Communications Manager

50,000 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
-11.16%-22.85%+50.45%-36.06% 185M
+0.21%-4.63%+55.34%+71.32% 68.92B
+1.66%+7.51%+8.12%+60.04% 51.9B
+3.14%+7.17%+12.48%+44.42% 48.73B
+3.45%+4.70%+33.44%+35.96% 43.13B
-2.20%+0.61%+281.88%+532.76% 41.48B
+6.43%+6.84%+18.32%+109.23% 39.96B
+1.28%+1.39%+11.69%+45.10% 30.6B
+2.47%-7.45%+35.95%+1.71% 26.01B
+1.74%-2.02%-13.55%-12.92% 22.27B
Average +0.70%-3.17%+49.41%+85.16% 37.32B
Weighted average by Cap. +1.90%-0.31%+52.82%+105.42%

Financials

2024 2025
Net sales 27.74B 20.64M 18.42M 17.12M 15.57M 29.3M 1.95B 29.83M 206M 80.47M 1.02B 77.45M 75.81M 3.26B 24.59B 18.29M 16.33M 15.17M 13.8M 25.97M 1.73B 26.44M 182M 71.31M 904M 68.64M 67.18M 2.89B
Net income -20.11B -14.96M -13.35M -12.41M -11.29M -21.24M -1.42B -21.62M -149M -58.34M -739M -56.15M -54.96M -2.37B -6.43B -4.78M -4.27M -3.97M -3.61M -6.79M -453M -6.91M -47.65M -18.64M -236M -17.95M -17.56M -756M
Net Debt -48.91B -36.38M -32.47M -30.18M -27.45M -51.65M -3.45B -52.58M -363M -142M -1.8B -137M -134M -5.75B -17.86B -13.29M -11.86M -11.02M -10.03M -18.87M -1.26B -19.21M -132M -51.81M -657M -49.87M -48.81M -2.1B
Projected Income Statement - Annual - Genome & Company
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
96
Date Price Change Volume
26-10-15 ₩4,220.00 -11.16% 680,224
26-10-14 ₩4,750.00 -2.66% 329,019
26-10-13 ₩4,880.00 -5.61% 815,504
26-10-12 ₩5,170.00 -5.48% 356,722
26-10-08 ₩5,470.00 +2.82% 643,488
  1. Stock Market
  2. Stocks
  3. A314130 Stock